Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027  NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completionPhase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and webcast at 8:30 am ET  THE WOODLANDS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishme ...